Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine‐induced killer cell therapy in hepatobiliary and pancreatic cancer

2022-04-11T10:07:44+00:00April 11th, 2022|

Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine‐induced killer cell therapy in hepatobiliary and pancreatic cancer Overall survival CONTACT US Summary The goal of this study was [...]

Effects of Dendritic Cell-activated and Cytokine-induced Killer Cell Therapy on 22 Children with Acute Myeloid Leukemia after Chemotherapy

2022-03-23T12:05:49+00:00March 23rd, 2022|

Effects of Dendritic Cell-activated and Cytokine-induced Killer Cell Therapy on 22 Children with Acute Myeloid Leukemia after Chemotherapy AML cancer cells CONTACT US Summary This study investigated the efficiency [...]

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

2022-02-23T16:08:22+00:00February 23rd, 2022|

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients Percentage of progression vs survival [...]

Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer

2022-02-15T09:02:44+00:00February 15th, 2022|

Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer Plasma samples CONTACT US Summary The study investigates a phase [...]

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study

2022-02-15T08:48:13+00:00February 15th, 2022|

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study MRI scan CONTACT US Summary DC loaded with proteins derived from autologous tumour [...]

The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

2022-02-15T08:35:56+00:00February 15th, 2022|

The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study After 2 cycles of infusion [...]

Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients

2022-02-08T10:38:01+00:00February 8th, 2022|

Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients Total responses CONTACT US Summary The purpose of this study is [...]

Autologous Dendritic Cells Combined with Cytokine-induced Killer Cells Synergize Low-dose Chemotherapy in Elderly Patients with Acute Myeloid Leuakemia

2022-02-08T10:30:39+00:00February 8th, 2022|

Autologous Dendritic Cells Combined with Cytokine-induced Killer Cells Synergize Low-dose Chemotherapy in Elderly Patients with Acute Myeloid Leukaemia Acute Myeloid Leukaemia CONTACT US Summary The goal of the study [...]

Immune Combination Therapy with NK Cell and Pembrolizumab Showed Therapeutic Efficacy in Treating Advanced Solid Tumors

2022-02-08T10:12:58+00:00February 8th, 2022|

Immune Combination Therapy with NK Cell and Pembrolizumab Showed Therapeutic Efficacy in Treating Advanced Solid Tumors Tumor size in the lungs before/after therapy CONTACT US Summary This study, conducted [...]

Go to Top